INTERVIEW: ImmunoGen prepares to capitalize on Kadcyla
This article was originally published in Scrip
Executive Summary
ImmunoGen is preparing to capitalize on US FDA approval in February for Kadcyla (ado trastuzumab emtansine) - the first approved cancer therapy that incorporates the Waltham, Massachusetts-based company's antibody-drug conjugate (ADC) technology.
You may also be interested in...
ImmunoGen’s Mirvetuximab Confidence Justified With Ovarian Cancer Win
The response rate, with five complete responses, exceeds known responses to standard-of-care chemotherapy in heavily pre-treated folate receptor alpha-high patients. A US FDA filing is on track for early 2022.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.